6533b852fe1ef96bd12ab621
RESEARCH PRODUCT
Peptide Receptor Radionuclide Therapy for Neuroendocrine Neoplasms in Germany: a Multi-Institutional Registry Study with Prospective Follow Up on 450 Patients
Samer EzziddinAlexander HaugMatthias MiedererDieter HörschBernd J. KrauseS. DunkelmannGabriele PöpperlRichard A. BaumHans-jürgen BiersackK. F. Gratzsubject
medicine.medical_specialtyPediatricsgenetic structuresPeptide receptorbusiness.industryRegistry studyHematologyNeuroendocrine tumorsmedicine.diseaseOncologyRadionuclide therapyotorhinolaryngologic diseasesmedicineIn patientRadiologyReceptorbusinesspsychological phenomena and processesdescription
68 Ga-DOTATOC PET in patients with neuroendocrine tumors (NET). We specifically looked for incremental lesions, defined as lesions only observed on one modality even after extensive retrospective evaluation of the other modality. Methods: Twenty patients with a metastasized NET underwent 111 In-pentetreotide
year | journal | country | edition | language |
---|---|---|---|---|
2013-06-01 | Annals of Oncology |